Freedom Investment Management Inc. Cuts Stock Holdings in Boston Scientific Corporation $BSX

Freedom Investment Management Inc. reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 11.4% during the 1st quarter, Holdings Channel reports. The fund owned 5,378 shares of the medical equipment provider’s stock after selling 691 shares during the quarter. Freedom Investment Management Inc.’s holdings in Boston Scientific were worth $543,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at $27,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at $31,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $106.42 on Wednesday. The company’s fifty day moving average price is $104.27 and its 200 day moving average price is $102.15. Boston Scientific Corporation has a 12 month low of $79.03 and a 12 month high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $157.69 billion, a P/E ratio of 63.35, a P/E/G ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business earned $0.62 EPS. Boston Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Morgan Stanley increased their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Needham & Company LLC restated a “buy” rating and issued a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. Barclays raised their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Finally, Leerink Partners initiated coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.